CEO Corner articles are written by presidents or CEOs of biopharmaceutical or medical device companies that create a drug or device. These articles discuss global industry trends, experiences, and challenges that biopharma CEOs and presidents can relate to and should be aware of.
Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.
There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.
Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.
A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.
The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.
Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.
With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.
All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.
Rich Daly, Chairman & CEO of Neuralstem, Inc., pens this month column and gives some enlightening anecdotes about what it takes to make "transformational" changes at a biopharma company.
Jeffrey Stein, Ph.D., president and CEO of Cidara Therapeutics, discusses what needs to be done now by drug companies and healthcare providers alike to stem the tide of emerging antimicrobial resistance, including collaboration to address market barriers.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing.
Tony Coles, M.D., former CEO of Onyx Pharmaceuticals, provides his perspective on Amgen’s $9.7 billion acquisition of Onyx.
Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.